REG - AstraZeneca PLC - AstraZeneca begins trading on NYSE

AstraZenecaAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260202:nRSB2712Ra&default-theme=true

RNS Number : 2712R  AstraZeneca PLC  02 February 2026

 

02 February 2026

 

AstraZeneca begins trading on the New York Stock Exchange

 

Ordinary shares now trade across the NYSE, LSE and STO under a harmonised
global listing structure

 

AstraZeneca today begins trading its ordinary shares on the New York Stock
Exchange (NYSE) for the first time, enabling more US investors to participate
in the Company's strong growth. With this change the trading of AstraZeneca
ordinary shares is now aligned across the NYSE, the London Stock Exchange
(LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.

Michel Demaré, Chair, AstraZeneca, said: "Today marks the start of an
exciting new period for AstraZeneca, one which we believe gives broader access
to the largest capital market in the world. This will allow even more
investors to participate in AstraZeneca's future. Our harmonised listing
across New York, London and Stockholm reflects strong shareholder support for
our growth strategy and positions AstraZeneca to deliver more innovative
medicines to more patients around the world."

Lynn Martin, President, NYSE Group said: "Today we are proud to welcome
AstraZeneca to the NYSE, where it joins a community of groundbreakers and
industry leaders. Through its listing on the world's largest and most liquid
capital market, the company is well-positioned to expand its global investor
base and accelerate its commitment to delivering innovation to patients and
the wider biopharmaceutical industry."

AstraZeneca's strong growth is driven both by its global reach and diverse
sources of business. Last year was a catalyst-rich period with new pipeline
readouts collectively representing a peak revenue opportunity of over $10
billion. With this momentum continuing into 2026, the Company has confidence
in reaching its 2030 ambition to grow annual revenue to $80bn and launch 20
new medicines. Looking beyond 2030, AstraZeneca is investing in transformative
technologies that have the potential to change the practice of medicine across
our portfolio.

AstraZeneca ordinary shares will continue to trade under the ticker symbol
"AZN" across the three exchanges. The Company's listing in the UK on the LSE
and in Sweden on the STO are unaffected by the move and remain included in
the FTSE 100 and OMX Stockholm 30 indices.

The prior listing of American Depositary Shares and the various US dollar
bonds issued by the Company and AstraZeneca Finance LLC (AstraZeneca US Bonds)
on Nasdaq in the US ceased on 30 January 2026. Trading of the AstraZeneca US
Bonds on the NYSE will commence immediately following the start of trading of
the ordinary shares on the NYSE.

 

 

 

 

 

Notes

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) . The contents of AstraZeneca's
website do not form part of this document and no one should rely on such
websites or the contents thereof in reading this document.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEAFESLKEAA



            Copyright 2019 Regulatory News Service, all rights reserved